ScreenPoint Medical, a Nijmegen, Netherlands-based company specializing in AI for breast cancer detection, has acquired Biomediq A/S, a Danish firm focused on quantitative imaging biomarkers.
The partnership, built on over a decade of collaboration, aims to integrate Biomediq’s risk assessment technology into ScreenPoint’s AI platform, Transpara.
Biomediq’s technology leverages Mammographic Texture Risk biomarkers to analyze 2D and 3D mammograms, providing insight into both short- and long-term breast cancer risk. This complements Transpara’s existing capabilities, which include lesion detection and breast density evaluation.
The combination was validated in a 2023 study published in Radiology, which demonstrated improved cancer risk prediction when these technologies were used together. The study also showed that incorporating this analysis could double early detection rates of interval cancers.
Dr. Andreas D. Lauritzen, the study’s lead author, will join ScreenPoint Medical to further develop Transpara’s risk assessment tools.
“Risk-stratified screening has long been proposed to optimize resources and patient care,” said Nico Karssemeijer, ScreenPoint’s co-founder and chief scientific officer. “Adding Biomediq’s technology strengthens Transpara’s ability to improve breast cancer risk assessment and detection.”
ScreenPoint recently launched Transpara 2.1, an updated version of its AI system. The tool includes enhanced breast density assessment, temporal comparison of mammograms, and other features aimed at optimizing radiology workflows.
